Diclofenac induced immune thrombocytopenia.

Department of Medicine, University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada.
The Journal of Rheumatology (Impact Factor: 3.17). 11/1990; 17(10):1403-4.
Source: PubMed

ABSTRACT We describe a patient with scleroderma who developed immune thrombocytopenia secondary to diclofenac on 2 occasions. Platelet count returned to normal with cessation of diclofenac and institution of prednisone.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diclofenac is a member of nonsteroidal anti-inflammatory drugs. In Turkey, ıt is often used as a analgesic. Diclofenac may very occasionally lead to spontaneous extensive ecchymosis and hematoma despite a normal coagulation parameters. In this paper, we report one patient who presented with spontaneous extensive ecchymosis and was diagnosed with a hematoma in the anterior chest wall associated with diclofenac use despite normal coagulation parameters. In countries like Turkey where NSAID are used extensively, drug history should be questioned in patients presenting with spontaneous bleeding and have normal coagulation parameters by physicians.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diclofenac is a nonsteroidal anti-inflammatory agent that is reported to cause serious hepatic injury in some patients. To investigate the possibility that protein adducts derived from reactive intermediates of diclofenac might be responsible for the hepatotoxicity produced by this drug, we recently developed polyclonal antisera that recognized protein adducts of diclofenac. In the present study, we have characterized further the diclofenac adducts in rat liver. Immunoblotting studies showed that diclofenac-labeled hepatic proteins were formed in a dose- and time-dependent manner in rats given diclofenac. Subcellular fractionation of liver homogenates from diclofenac-treated rats showed that a 50-kDa microsomal protein and 110-, 140-, and 200-kDa plasma membrane proteins were labeled preferentially. Immunofluorescence studies of isolated hepatocytes and immunohistochemical analysis of liver slices from diclofenac-treated mice and rats confirmed that plasma membrane proteins were labeled by diclofenac metabolites and showed that the bile canalicular domain of the plasma membrane was a major site of diclofenac adduct formation. Additionally, we found that cytochrome P-450 and UDP-glucuronosyltransferase, but not acyl-CoA synthase, catalyzed the formation of reactive intermediates of diclofenac that were bound covalently to proteins in vitro. The metabolites catalyzed by cytochrome P-450 in vitro were bound exclusively to a 50-kDa microsomal protein, even in the presence of albumin. In contrast, the 110-, 140-, and 200-kDa plasma membrane proteins as well as others appeared to be labeled when diclofenac was activated by UDP-glucuronosyltransferase.(ABSTRACT TRUNCATED AT 250 WORDS)
    Chemical Research in Toxicology 07/1994; 7(4):575-82. DOI:10.1021/tx00040a014 · 4.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A case of diclofenac-induced thrombocytopenic purpura in a 59-year-old woman is described. Unlike the majority of earlier cases, ours was associated with renal insufficiency and jaundice. Despite the dramatic clinical picture, with severe thrombocytopenia and marked renal insufficiency, the prognosis appears to be excellent, as is shown in our case and in similar ones reported in the literature. A high dose of steroids is the treatment of choice.
    Journal of Internal Medicine 01/1992; 230(6):543-7. DOI:10.1111/j.1365-2796.1991.tb00487.x · 5.79 Impact Factor